CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Polysorbate 80	SPECIFIC	*USP35–NF30*	1920	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second*	Line 5 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	TESTS/*Fats and Fixed Oils, Peroxide Value <401>*						*Supplement to USP36–NF31*	*Analysis*: Change 0.01 M sodium thiosulfate to: 0.01 M sodium thiosulfate VS
Ampicillin Sodium	SPECIFIC TESTS/*pH <791>*	*USP35–NF30*	2213	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 2: Change text of *Sample solution* from 10.0 mg/mL to: 10.0 mg/mL of ampicillin
Anhydrous Dibasic Calcium Phosphate	IM PUR ITIES/*Heavy Metals, Method I <231>*	*USP35–NF30*	2464	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Test preparation*: Change Warm 1.3 g with 3 mL of 3 N hydrochloric acid to completely dissolve. to: Warm 1.3 g with 3 mL of 3 N hydrochloric acid until no more dissolves.
Tramadol Hydrochloride	IM PUR	*USP35–NF30*	4905	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to*	Line 5 of *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Tablets	ITIES/*Organic Impurities/Procedure*						*USP36–NF31*	Change Result = $(r_U/r_S) \times (C_S/C_U) \times (1/F) \times 0.1$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$
Esomeprazole Magnesium Delayed-Release Capsules	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP35–NF30*	5473	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Change *Buffer, Diluent, Mobile phase, System suitability, and Chromatographic system*: Proceed as directed in the *Assay*. to: *Buffer, Mobile phase, System suitability, and Chromatographic system*: Proceed as directed in the *Assay*.
Cefepime Hydrochloride	IMPURITIES/*Organic Impuri*	*Second Supplement to USP35–NF30*	5923	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 5 of *Chromatographic system*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ties/Procedure 1: Limit of N-Methylpyrrolidine							*Column:* 4.0-mm x 25-cm; 5-µm packing L##[1] to: *Column:* 4.0-mm x 25-cm; 5-µm packing L76 AND Delete corresponding footnote: "Available as Metrosep C4-250."
Antibiotics—Microbial Assays	*Turbidimetric Method*	*USP35–NF30*	74	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 8 of *Analysis*: Change Include in each rack 1–2 control tubes containing 1 mL of the inoculum medium (see *Table 8*) but no antibiotic. to: Include in each rack 1–2 control tubes

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								containing 1 mL of the test diluent (see *Table 7*) but no antibiotic.
Aminosalicylate Sodium Tablets	*Limit of m-aminophenol*	*USP35–NF30*	2178	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Test solution*: Change Use the *Assay preparation*, prepared as directed in the *Assay*. to: Weigh and finely powder not fewer than 20 Tablets. Transfer an accurately weighed portion of the powder, equivalent to about 690 mg of aminosalicylate sodium, to a 100-mL low-actinic volumetric flask. Add 50 mL of *Mobile phase*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and shake for about 5 minutes. Dilute with *Mobile phase* to volume, and mix. Filter, and transfer 10.0 mL of the clear filtrate to a low-actinic, 100-mL volumetric flask containing 10.0 mL of *Internal standard solution*, dilute with *Mobile phase* to volume, and mix.
Dibasic Calcium Phosphate Dihydrate	IM PUR ITIES/*Heavy Metals, Method I <231>*	*USP35–NF30*	2463	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Test preparation*: Change Warm 1.3 g with 3 mL of 3 N hydrochloric acid to completely dissolve. to: Warm 1.3 g with

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								3 mL of 3 N hydrochloric acid until no more dissolves.
Moxifloxacin Ophthalmic Solution	*Related compounds/Test 1*	*USP35–NF30*	3960	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 4 of *Chromatographic system*: Delete The flow rate is about 0.5 mL per minute.
Containers—Glass	SPECIFIC TESTS/ *Hydrolytic Resistance/Method*	*First Supplement to USP35–NF30*	5150	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	In the Note in line 11 of *Titration*: Change Rinse the grains by swirling with three 15-mL portions of Purified Water, and add the washings to the main solution. to: Rinse the grains by swirling with three 15-mL portions of Carbon Dioxide-Free Water, and add the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								washings to the main solution.
Omega-3-Acid Ethyl Esters Capsules	SPECIFIC TESTS/ *Microbial Enumeration <61>*	*First Supplement to USP35–NF30*	5524	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 2: Change 10^3 to: 10^3 cfu/g AND Line 3: Change 10^2 to: 10^2 cfu/g
Olanzapine Tablets	IM PUR ITIES/*Organic Impurities*	*Revision Bulletin (Official July 01, 2012)*	Online	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 11 of *Analysis*: Change C_U = concentration of olanzapine in the *Sample solution* (mg/mL) to: C_U = nominal concentration of olanzapine in the *Sample solution* (mg/mL)
Polysorbate 80	SPECIFIC TESTS/*Fats and Fixed Oils, Saponification*	*USP35–NF30*	1920	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 3 of *Analysis*: Change 0.5 N alcoholic

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Value <401>							potassium hydroxide to: 0.5 N alcoholic potassium hydroxide VS Line 6 of *Analysis*: Change 0.5 N hydrochloric acid to: 0.5 N hydrochloric acid VS
GANCICLOVIR ORAL SUSPENSION	ASSAY	*USP35–NF30*	3319	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 1 of *Internal standard solution*: Change 4 mg per mL to: 0.4 mg per mL
POLYVINYL ALCOHOL	*Identification* test *C*	*USP35–NF30*	4351	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 5: Change Add 10 mL of alcohol to the remaining 5 mL of the polyvinyl alcohol solution,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and mix to: Add 10 mL of alcohol to the remaining 2 mL of the polyvinyl alcohol solution, and mix.
TYROSINE	IMPURITIES/*Heavy Metals* <231>	*USP35–NF30*	4976	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 1: Change *Method I* to: *Method II*
TRIBASIC CALCIUM PHOSPHATE	IDENTIFICATION/*Test A*	*USP35–NF30*	1719	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 1 of the *Sample solution*: Change Dissolve 100 mg in 5 mL of diluted nitric acid. to: A solution in a slight excess of nitric acid
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES	PERFORMANCE TESTS/*Dissolution* <711>	*First Supplement to USP35–NF30*	5473	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 4 of *Medium*: Change and adjust with 2 N hydrochloric acid or 2 N sodium, if

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								necessary, to a pH to: and adjust with 2 N hydrochloric acid or 2 N sodium hydroxide, if necessary, to a pH
POLYETHYLENE OXIDE	IMPURITIES/*Organic Impurities/Procedure: Limit of Free Ethylene Oxide*	*USP35–NF30*	1906	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 2 of *System suitability*: Change *Samples: Standard stock solution* and *Standard solution C* to: *Sample: Standard solution C*
ELEMENTAL IMPURITIES—LIMITS	DRUG SUBSTANCE AND EXCIPIENTS	*Second Supplement to USP35–NF30*	5633	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Rows 11 and 15 of *Column 2* of *Table 2*: Change 100 to: 10 AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Rows 11 and 15 of *Column 3* of *Table 2*: Change 10 to: 1.0 AND Row 11 of *Column 4* of *Table 2*: Change 1.5 to: 0.15 AND Row 15 of Column 4 of Table 2: Change 30 to: 3.0
ZEIN	IDENTIFICATION/*C. SDS-Polyacrylamide Gel Electrophoresis*	*USP35–NF30*	2019	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Lines 1 and 2 of the *Acceptance criteria*: Change Zein has two major bands: the ? band is at 21–25 kDa, and the ? band is at

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								17–18 kDa. to: Zein has two major bands for ?-zein at 19–26 kDa.
AZITHROMYCIN FOR INJECTION	IMPURITIES/*Limit of Aminoazithromycin, Formamido Analog, Methylformamido Analog, and 3?-De(dimethylamino)-3?-oxoazithromycin*	*Second Supplement to USP35–NF30*	5910	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Row 11 of *Table 2*: Change 3?-Demethyl-3?-*N*-[(4-methylphenyl)sulfonyl]azithromycin to: 3?-*N*-Demethyl-3?-*N*-[(4-methylphenyl)sulfonyl]azithromycin
CHLOROPHYLLIN COPPER COMPLEX SODIUM	SPECIFIC TESTS/*Loss on Drying* <231>	*USP35–NF30*	2628	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 1: Change 150° to: 105°
METRONIDAZOLE	*Related compounds*	*USP35–NF30*	3905	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 19 of *Procedure*: Change *r*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								r_i is the peak response for any unspecified degradation product peak in the *Test solution* to: r_i is the peak response for any single unspecified impurity in the *Test solution*
PRILOCAINE AND EPINEPHRINE INJECTION	*Assay for epinephrine*	*USP35–NF30*	4411	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 7 of *Procedure*: Change 183.21/333.30 to: 183.20/333.29 AND Line 8 of *Procedure*: Change 183.21 and 333.30 to: 183.20 and 333.29
DESCRIPTION AND	*Ethylcellulose Dispersion Type*	*USP35–NF30*	1118	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to*	Lines 3 and 4: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SOLUBILITY	*B*						*USP36–NF31*	in toluene, in chloroform, and in ethyl acetate; insoluble in water, in glycerin, and in propylene glycol. to: in tetrahydrofuran, and in ethyl acetate; insoluble in water and in chloroform.
DELIVERABLE VOLUME	ACCEPTANCE CRITERIA/*For Multiple-Unit Containers*	*First Supplement to USP35–NF30*	5154	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	*Figure 1*, right branch, left box: Change Volume of 1 more containers is less than 95% LV to: Volume of 1 or more containers is less than 95% LV
MAGNESIUM STEARATE	IM PUR ITIES/*Chloride*	*USP35–NF30*	1847	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 3: Change 0.020 N sulfuric acid (1.0%)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	and Sulfate, Sulfate <221>							to: 0.020 M sulfuric acid (1.0%)
TACROLIMUS	IM PUR ITIES/ *Procedure 2*	*First Supplement to USP35–NF30*	5538	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Footnote h of *Table 3*: Change (3*S*,4*R*,5*S*,8*S*,9*E*,12*S*,14*S*,15*R*,16*S*,18*R*,19*R*,26a*S*)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-{(*E*)-2-[(1*R*,3*R*,4*R*)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3*H*-pyrido[2,1-*c*][1,4]oxaazacyclotricosine-1,7,20,21(4*H*,23*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-tetrone. to: (3*S*,4*R*,5*S*,8*R*,9*E*,12*S*,14*S*,15*R*,16*S*,18*R*,19*R*,26a*S*)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-{(*E*)-2-[(1*R*,3*R*,4*R*)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3*H*-pyrido[2,1-*c*][1,4]oxaazacyclotricosine-1,7,20,21(4*H*,23*H*)-tetrone.
SODIUM HYDROXIDE	ASSAY/ *Procedure*	*USP35–NF30*	1955	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 10 of *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Result = {[(V_{S1} ? V_B) × N × F_1]/W} × 100 to: Result = {[(V_{S2} ? V_B) × N × F_1]/W} × 100 AND Line 11 of *Analysis*: Change V_{S1} to: V_{S2}
ELEMENTAL IMPURITIES—LIMITS	DRUG PRODUCTS/*Large Volume Parenterals*	*Second Supplement to USP35–NF30*	5633	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Row 13 of *Column 4* of *Table 1*: Change 250 to: 10
ALPRAZOLAM ORALLY-DISINTEGRATING TABLETS	IMPURITIES/ *Procedure*	*USP35–NF30*	2106	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Change the subsection *Buffer* and *Diluent*: Prepare as directed in the *Assay*. to: *Diluent*: Prepare as directed in the *Assay*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Buffer: 6.8 g/L of monobasic potassium phosphate in water. Adjust with phosphoric acid to a pH of 3.0.
INDINAVIR SULFATE	OTHER COMPONENTS/*Procedure 2: Content of Alcohol*	*USP35–NF30*	3489	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 6 of *Chromatographic system* in the subsection *Column*: Change G14 to: G16
POVIDONE	IMPURITIES/*Limit of Aldehydes*	*USP35–NF30*	4379	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 15 of *Analysis*: Change Result = 10 × (*C*/*W*) × {[(A_{U2} ? A_{U1}) × (A_{B2} ? A_{B1})]/[(A_{S2} ? A_{S1}) ? (A_{B2} ? A_{B1})]} to: Result = 100 × (C_S/C_U) × {[(A_{U2} ? A_{U1}) ? (A_{B2} ? A_{B1})]/[(A_{S2} ? A_{S1}) ? (A_{B2} ? A

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_{B1}$)]} AND Line 17 of *Analysis*: Change *C* = concentration of acetaldehyde in the *Standard solution* (mg/mL) W = weight of Povidone taken (g) to: C_S = concentration of acetaldehyde in the *Standard solution* (mg/mL) C_U = concentration of *Sample solution* (mg/mL)
VINORELBINE TARTRATE	ASSAY/ *Procedure*	*USP35–NF30*	5027	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 1 of *Relative standard deviation* in *System suitability*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CALCIUM SULFATE	ASSAY/ *Procedure*	*USP35–NF30*	1724	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Change NLT 2.0% to: NMT 2.0% Line 5 of *Titrimetric system*: Delete the subsection *Blank*: 100 mL of water and 4 mL of 3 N hydrochloric acid AND Line 11 of *Analysis*: Delete the sentence Perform a blank determination. AND Line 13 of *Analysis*: Change Result = [(*V* ? *B*) × *N* × *F* × 100]/*W* to: Result = [(*V* × *N* × *F*)/*W*] × 100 AND Line 15 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES	IMPURITIES/*Organic Impurities*	*First Supplement to USP35–NF30*	5473	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	*Analysis*: Delete *B* = volume of titrant consumed by the Blank (mL) Line 1 of *Sample solution*: Change Transfer a portion of the powdered pellets, from the Capsule content, equivalent to 80–90 mg of esomeprazole, to a 200-mL volumetric flask, add 20 mL of methanol, and shake for 30 s. to: Transfer a portion of the powdered pellets (about 80–90 mg), from the Capsule

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								content, to a 200-mL volumetric flask, add 20 mL of methanol, and shake for 30 s.
POLYSORBATE 20	SPECIFIC TESTS/*Acid Value*	*USP35–NF30*	1919	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 1 of *Sample*: Change 10.0 to: 10.0 g
ELEMENTAL IMPURITIES—LIMITS	ANALYTICAL TESTING	*Second Supplement to USP35–NF30*	5633	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 6: Change Pd to: Pb
ACETAZOLAMIDE FOR INJECTION	ASSAY	*USP35–NF30*	2063	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 19: Change $25C(A_U/A_S)$ to: $250C(A_U/A_S)$
AZITHROMYCIN FOR INJECTION	IMPURITIES/*Limit of Azithromycin N-Oxide, Desosaminylazithromycin, and N-Demethylazithromycin*	*Second Supplement to USP35–NF30*	5910	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 5 of *Analysis*: Change Result = $(r_U/r_S) \times (C_S/C_U) \times P \times F \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times P \times$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUTICASONE PROPIONATE	IMPURITIES/*Organic Impurities*	*USP35–NF30*	3261	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	100 Line 1 of the *Sample solution*: Change 2.0 mg/mL to: 0.2 mg/mL
NAFTIFINE HYDROCHLORIDE GEL	*Content of alcohol*	*USP35–NF30*	3983	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 4 of *Procedure*: Change Calculate the quantity, in mg, of C_2H_5OH in the portion of Gel taken by the formula: to: Calculate the percentage of C_2H_5OH in the portion of Gel taken by the formula:
RIBAVIRIN TABLETS	ASSAY/*Procedure*	*USP35–NF30*	4544	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 5 of *System suitability* in subsection *Tailing factor*: Change NLT 2.0

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: NMT 2.0
BENTONITE	IDENTIFICATION/*A. X-Ray Diffraction* <941>	*USP35–NF30*	1705	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 4 of *Acceptance criteria*: Change from the pattern of *Sample B* is 1.492 and 1.504 Å. to: from the pattern of *Sample B* is between 1.492 and 1.504 Å.
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/*Dissolution* <711>/*Test 3*	*First Supplement to USP35–NF30*	5460	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 2 of *Analysis*: Change *Samples*: *Acid stage standard solution*, *Buffer stage standard solution*, *Acid stage sample solutions*, and *Buffer stage sample solutions* to: *Samples*: *Acid stage standard solution*, *Buffer*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								stage standard solution, and *Sample solutions*
METHYL ALCOHOL	ASSAY/ *Procedure*	*USP35–NF30*	1865	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 9 of *System suitability*: Change *Tailing factor*: NLT 1.5 for methyl alcohol, *System suitability solution* to: *Tailing factor*: NMT 1.5 for methyl alcohol, *System suitability solution*
TACROLIMUS CAPSULES	IM PUR ITIES/ *Procedure 2*	*First Supplement to USP35–NF30*	5541	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Footnote j of *Table 5*: Change (3*S*,4*R*,5*S*,8*S*,9*E*,12*S*,14*S*,15*R*,16*S*,18*R*,19*R*,26a*S*)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-hexadecahydro-5,19-dihydroxy-3-{(*E*)-2-[(1*R*,3*R*,4*R*)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3*H*-pyrido[2,1-*c*][1,4]oxaazacyclotricosine-1,7,20,21(4*H*,23*H*)-tetrone. to: (3*S*,4*R*,5*S*,8*R*,9*E*,12*S*,14*S*,15*R*,16*S*,18*R*,19*R*,26a*S*)-5,6,8, 11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-{(*E*)-2-[(1*R*,3*R*,4

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3*H*-pyrido[2,1-*c*][1,4]oxaazacyclotricosine-1,7,20,21(4*H*,23*H*)-tetrone.
TREHALOSE	ADDITIONAL REQUIREMENTS/*USP Reference Standards* <11>	*USP35–NF30*	2007	28-Sep-2012	1-Oct-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 2: Delete USP Glycerin RS

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 24
- Page 25
- Page 26
- Page 27